COMP <GO>
EXEL vs UNH // FORWARD P/E MULTIPLE
Exelixis Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: EXEL 9
— UNH 6
▲ FORWARD P/E MULTIPLE LEADER: UNH
LAST: $69.39 (+4.82%) • MKT CAP: $16.40B
forward-pe
19.5x
LAST: $406.97 (-0.96%) • MKT CAP: $364.66B
forward-pe
17.1x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (EXEL VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | EXEL | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | 88.57% | +7.43 | EXEL | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 35.10% | 11.47% | +23.63 | EXEL | /roic <GO> |
| EV/EBITDA & P/E Valuation | 18.4x | 16.4x | +1.95 | UNH | /valuation <GO> |
| Free Cash Flow Yield | 5.34% | 6.48% | -1.14 | UNH | /fcf-yield <GO> |
| Operating Margin | 37.60% | 4.82% | +32.78 | EXEL | /operating-margins <GO> |
| Net Profit Margin | 33.70% | 3.14% | +30.56 | EXEL | /net-margins <GO> |
| Revenue Growth (YoY) | 7.00% | 6.46% | +0.54 | EXEL | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 16.64 | 3.12 | +13.52 | EXEL | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | EXEL | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.80% | 6.74% | +0.06 | UNH | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 81.7 | 56.0 | +25.60 | EXEL | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.96 | 0.33 | +0.63 | EXEL | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 19.5x | 17.1x | +2.41 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $16.40B | $364.66B | -$348.26B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | EXEL REV | UNH REV | EXEL GROSS % | UNH GROSS % | EXEL FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.32B | $447.57B | 96.4% | 88.7% | $875.8M | $16.07B |
| FY 2024 | $2.17B | $400.28B | 96.5% | 88.3% | $671.5M | $20.70B |
| FY 2023 | $1.83B | $371.62B | 44.0% | 89.6% | $251.0M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
EXEL // BETA 0.96
UNH // BETA 0.33